InxMed Overview
- Status
-
IPO Registration
- Employees
-
80
- Latest Deal Type
-
IPO
- (Announced)
- Investors
-
10
InxMed General Information
Description
Developer of cancer therapeutics designed to treat cancer. The company currently has pharmaceuticals targeting pancreatic, ovarian, gastric and other forms of cancer, enabling healthcare professionals to prescribe more effective treatments to patients.
Contact Information
Website
www.inxmed.comCorporate Office
- Floor 3, Building D-2, Building 16, Tree House
- Number 73 Tanmi Road, Jiangbei New District
- Nanjing, Jiangsu 210000
- China
Corporate Office
- Floor 3, Building D-2, Building 16, Tree House
- Number 73 Tanmi Road, Jiangbei New District
- Nanjing, Jiangsu 210000
- China
InxMed Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. IPO | 25-Aug-2025 | Announced | Clinical Trials - General | |||
| 8. Later Stage VC (Series C) | 22-Aug-2025 | Completed | Clinical Trials - General | |||
| 7. Debt - General | 21-Jul-2022 | Completed | Clinical Trials - General | |||
| 6. Early Stage VC (Series B1) | 13-Apr-2022 | Completed | Clinical Trials - General | |||
| 5. Secondary Transaction - Private | 29-Jul-2021 | Completed | Clinical Trials - General | |||
| 4. Early Stage VC (Series B) | 03-Mar-2022 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series A1) | 04-Sep-2020 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 31-Dec-2018 | $16M | $18.8M | Completed | Startup | |
| 1. Early Stage VC | 31-Oct-2018 | $2.8M | $2.8M | Completed | Startup |
InxMed Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
InxMed Patents
InxMed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026194850-A1 | New use | Pending | 17-Mar-2025 | ||
| WO-2026149525-A1 | Antibody targeting integrin α2β1 or antigen-binding fragment thereof, and use thereof | Pending | 10-Jan-2025 | ||
| WO-2026139018-A1 | Fak inhibitor | Pending | 27-Dec-2024 | ||
| WO-2026086879-A1 | Fak inhibitor | Pending | 25-Oct-2024 | ||
| WO-2026026944-A1 | New use | Pending | 02-Aug-2024 |
InxMed Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
InxMed Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Fosun Health Capital | Corporate Venture Capital | Minority | ||
| Kunnuo Tianqin Venture Capital | Corporate Venture Capital | Minority | ||
| Proxima Capital | Venture Capital | Minority | ||
| Shanghai Innovation Bank | Merchant Banking Firm | Minority | ||
| Hyfinity Investments | Growth/Expansion | Minority |
InxMed FAQs
-
Where is InxMed headquartered?
InxMed is headquartered in Nanjing, China.
-
What is the size of InxMed?
InxMed has 80 total employees.
-
What industry is InxMed in?
InxMed’s primary industry is Drug Discovery.
-
Is InxMed a private or public company?
InxMed is a Private company.
-
What is InxMed’s current revenue?
The current revenue for InxMed is .
-
How much funding has InxMed raised over time?
InxMed has raised $132M.
-
Who are InxMed’s investors?
Fosun Health Capital, Kunnuo Tianqin Venture Capital, Proxima Capital, Shanghai Innovation Bank, and Hyfinity Investments are 5 of 10 investors who have invested in InxMed.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
